MedTrace Logo

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-07-03

Study results available
· View outcomes & findings →

Summary

To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is suppressed from attacking these special tumor fighting cells.

Conditions

  • Metastatic Melanoma
  • Locally Advanced Refractory/Recurrent Melanoma
  • Metastatic Head and Neck Cancer
  • Locally Advanced Refractory/Recurrent Head and Neck Cancer

Interventions

BIOLOGICAL

Autologous Tumor Infiltrating Lymphocytes

Autologous TILs

BIOLOGICAL

High-Dose Interleukin 2

720,000 IU/kg every 8 hours for up to 15 doses

Sponsors & Collaborators

  • Immunotherapy Foundation

    collaborator UNKNOWN

  • Gregory Daniels

    lead OTHER

Principal Investigators

  • Gregory Daniels, MD, PhD · University of California, San Diego

  • Ezra Cohen, MD · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2023-01-26
Completion
2023-01-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03991741 on ClinicalTrials.gov